Targeted inhibition of Bcl-xL following radiation reduces tumourigenesis in preclinical models of H3K27M-altered diffuse midline glioma
Authors: Vardon Ashley , Haston Scott , Guiho Romain , Carvahlo Diana , Carter Rebecca , Boult Jessica , Gharai Daniel , Santhakumar Diwakar , Cloete Ielyaas , Gray James , Apps John , Ogunbiyi Olumide , Zhou Daohong , Zheng Guangrong , Martínez-Máñez Ramón , Lythgoe Mark , Donovan Laura , Carcaboso Angel Montero , Williams Owen , Gil Jesus , Jacques Thomas , Dean Jamie , Michod David , Jones Chris , Hargrave Darren , Martinez-Barbera Juan-Pedro 
Published: December 2024

Background

Diffuse midline gliomas (DMGs) with histone H3K27M mutations represent a devastating paediatric brain cancer characterized by abysmal prognosis and limited treatment options. The only approved treatment is radiotherapy (RT), but most of the tumours relapse with fatal consequences. In this study, we sought to investigate whether irradiation leads to senescence induction and explore the efficacy of senolytics against DMG.

Methods

We have characterised the senescent phenotype of five genetically heterogeneous H3K27M-altered human DMG cell lines, combining cellular and/or molecular approaches. The sensitivity of senescent cells to Bcl-xL inhibition has been demonstrated in dose/response curves in vitro and in a PDX model of DMG.

Results

Here, we show that ionizing radiation induces senescence and SASP responses in both TP53 mutant and wild-type H3K27M-altered human DMG cell lines. We identify Navitoclax as a potent senolytic agent that selectively targets senescent DMG cells into apoptosis by inhibiting Bcl-xL. Related compounds, such as a proteolysis-targeting chimera (PROTAC)-mediated Bcl-xL degradation and a galacto-conjugated form of Navitoclax also show an effective senolytic activity in senescent cancer cells. Finally, we show that a combination therapy of irradiation and Navitoclax results in reduced tumor burden and increased mouse survival in an orthotopic xenograft DMG model.

Conclusion

These results offer a rationale for further clinical development of senolytic therapies as part of multimodal treatment approaches for DMG patients/

Key Points

Ionising irradiation induces senescence in human DMG cells independently of the p53 status.

Bcl-xL inhibition results in apoptosis of human DMG senescent cells in synergy with irradiation.

Combination of irradiation and BcL-xL inhibition reduces tumourigenesis in a PDX model of DMG.

Importance of the Study

H3K27M-altered DMG are devastating paediatric tumours with an abysmal prognosis. The only approved treatment is radiotherapy but this is palliative and tumours almost always relapse with fatal consequences for the patients. In this study, we show that radiotherapy results in senescence induction in five genomically heterogeneous human DMG cell lines. We identify that drugs targeting the anti-apoptotic protein Bcl-xL show a strong senolytic activity in conjunction with radiotherapy both in vitro in DMG cells and in vivo in a PDX model of H3K27M-altered DMG. Treatment with Bcl-xL inhibitor Navitoclax, or related compounds targeting Bcl-xL protein degradation or containing a galactose conjugated form of Navitoclax results in DMG cancer cell apoptosis. As several of these inhibitors are currently being tested in ongoing clinical trials against other diseases, our data support the use of Bcl-xL inhibition mediated senolytics as an adjuvant therapy to radiotherapy to potentially improve outcomes in this challenging disease setting.